These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33914350)

  • 41. Changes in blood counts after the administration of granulocyte-colony-stimulating factor and the collection of peripheral blood stem cells from healthy donors.
    Stroncek DF; Clay ME; Smith J; Ilstrup S; Oldham F; McCullough J
    Transfusion; 1996 Jul; 36(7):596-600. PubMed ID: 8701454
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.
    Di Leo A; Bajetta E; Nolè F; Biganzoli L; Ferrari L; Oriana S; Riboldi G; Bohm S; Spatti G; Raspagliesi F
    Br J Cancer; 1994 May; 69(5):961-6. PubMed ID: 7514030
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum levels of endogenous thrombopoietin and granulocyte-colony stimulating factor in patients with acute or lymphoma type adult T-cell leukemia during multicycle chemotherapy.
    Lin XY; Hanada S; Uozumi K; Utsunomiya A; Suzuki S; Shimotakahara S; Takeuchi S; Takatsuka Y; Arima T
    Leuk Lymphoma; 2002 Feb; 43(2):343-9. PubMed ID: 11999567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.
    Jolis L; Carabantes F; Pernas S; Cantos B; López A; Torres P; Funes C; Caballero D; Benedit P; Salar A;
    Eur J Cancer Care (Engl); 2013 Jul; 22(4):513-21. PubMed ID: 23730920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low doses of colony-stimulating factors lead to resolution of neutropenia in cancer patients through increased levels of dihydrofolate reductase.
    Iqbal MP; Burney IA
    Pak J Pharm Sci; 2014 Mar; 27(2):245-8. PubMed ID: 24577909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.
    Gianni AM; Bregni M; Siena S; Orazi A; Stern AC; Gandola L; Bonadonna G
    J Clin Oncol; 1990 May; 8(5):768-78. PubMed ID: 2185337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer.
    Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
    Am J Clin Oncol; 2000 Jun; 23(3):278-82. PubMed ID: 10857893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lurbinectedin-induced thrombocytopenia: the role of body surface area.
    Papachristos A; Ratain MJ
    Cancer Chemother Pharmacol; 2022 May; 89(5):573-575. PubMed ID: 35362793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.
    Barrett JA; Greene D; Lakshmikanthan S; Kolli P; Chawla S; Lebel F
    J Clin Pharmacol; 2021 Feb; 61(2):204-210. PubMed ID: 32827162
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of myelosuppression on quality of life of patients treated with chemotherapy.
    Crawford J; Herndon D; Gmitter K; Weiss J
    Future Oncol; 2024; 20(21):1515-1530. PubMed ID: 38587388
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
    Jones SE; Khandelwal P; McIntyre K; Mennel R; Orr D; Kirby R; Agura E; Duncan L; Hyman W; Roque T; Regan D; Schuster M; Dimitrov N; Garrison L; Lange M
    J Clin Oncol; 1999 Oct; 17(10):3025-32. PubMed ID: 10506596
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
    Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
    Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.
    Dahut W; Harold N; Takimoto C; Allegra C; Chen A; Hamilton JM; Arbuck S; Sorensen M; Grollman F; Nakashima H; Lieberman R; Liang M; Corse W; Grem J
    J Clin Oncol; 1996 Apr; 14(4):1236-44. PubMed ID: 8648379
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Delayed Granulocyte Colony-Stimulating Factor (G-CSF) Administration after Chemotherapy Reduces Total G-CSF Doses without Affecting Neutrophil Recovery in a Randomized Clinical Study in Children with Solid Tumors.
    Yankelevich M; Hoogstra DJ; Abrams J; Chu R; Bhambhani K; Taub JW
    Pediatr Hematol Oncol; 2020 Nov; 37(8):665-675. PubMed ID: 32643500
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
    Michel G; Landman-Parker J; Auclerc MF; Mathey C; Leblanc T; Legall E; Bordigoni P; Lamagnere JP; Demeocq F; Perel Y; Auvrignon A; Berthou C; Bauduer F; Pautard B; Schneider P; Schaison G; Leverger G; Baruchel A
    J Clin Oncol; 2000 Apr; 18(7):1517-24. PubMed ID: 10735900
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration.
    Higa GM; DeVore RF; Auber ML; Lynch JP; Landreth KS
    Pharmacotherapy; 1998; 18(1):1-8. PubMed ID: 9469674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.